07.06.26 -- Solving Glycoengineering Challenges Could Begin At The Cell Line

Explore a scalable protocol for T cell activation and expansion, designed to enhance immunotherapy workflows. This approach ensures robust T cell growth, viability, and memory phenotypes.

Middlesex County, NJ, is a premier life sciences hub, attracting major biopharma leaders, entrepreneurs, and investors to accelerate global medical innovation.

A high-performance, helper virus-free stable producer cell line is derived from proprietary high-producer HEK293 cells and is cultivated in a chemically defined, serum-free, ADCF medium in suspension.

Learn about designing large Design-of-Experiment (DOE) upstream process development studies and the elements that could positively or negatively affect your throughput.

Discover how an optimized, end-to-end development strategy can help sponsors reach key clinical milestones faster and bring potentially life-saving therapies to patients sooner.

In this presentation, experts provide insight into transposase-mediated genome engineering, genetic quality control, and the maintenance of genetic stability in cell line generation.

Understand the manufacturing challenges where rapid cell expansion often conflicts with therapeutic secretion profiles, requiring sophisticated quality control and donor selection strategies.

Examine scalable strategies for high-yield adherent cell culture. Learn how gas-permeable technology optimizes MSC expansion, viral vector production, and extracellular vesicle secretion.

Legacy methods often mask critical impurities. Find out why traditional blotting may be jeopardizing your regulatory data and how to implement more sensitive, objective alternatives.

Streamline viral vector manufacturing with perfusion technologies that reduce costs and improve scalability. See how a tangential flow depth filtration system enhances yield and quality.